Search
Deramciclane
go.drugbank.com/drugs/DB06512InvestigationalDeramciclane (EGIS-3886) is used for the treatment of a number of anxiety disorders. … Deramciclane differs from other anti anxiety medications in that it is not a benzodiazepine and so has a different structure and target.
Zatebradine
go.drugbank.com/drugs/DB21228ExperimentalZatebradine is a small molecule drug. The usage of the INN stem '-bradine' in the name indicates that Zatebradine is a bradycardic agent. Zatebradine has a monoisotopic molecular weight of 456.26 Da.
Categories: Compounds used in a research, industrial, or household settingVSF-173
go.drugbank.com/drugs/DB05753InvestigationalVSF-173 is an oral small molecule. It is an oral compound that has demonstrated effects on animal sleep/wake patterns and gene expression patterns suggestive of a stimulant effect. … It is developed for the treatment of excessive sleepiness. Study shows that VSF-173 possesses a novel mechanism to address disorders of excessive sleepiness.
Novaferon
go.drugbank.com/drugs/DB16483InvestigationalCategories: Experimental Unapproved Treatments for COVID-19SVV-001
go.drugbank.com/drugs/DB06129InvestigationalSVV-001 is investigated for use/treatment in cancer/tumors and lung cancer. SVV-001 is a solid. … SVV-001 (Seneca Valley Virus) is a novel native picornavirus being developed as a systemically deliverable oncolytic virus for treatment of human cancers with neuroendocrine features.
Alprenolol
go.drugbank.com/drugs/DB00866ApprovedWithdrawnAlprenolol is no longer marketed by AstraZeneca, but may still be available in generic varieties. … One of the adrenergic beta-antagonists used as an antihypertensive, anti-anginal, and anti-arrhythmic agent.
STC3141
go.drugbank.com/drugs/DB16475InvestigationalSTC3141, was investigated in clinical trial NCT04880694 to evaluate its safety and effect in subjects with severe COVID-19 pneumonia.
Categories: Experimental Unapproved Treatments for COVID-19Brilaroxazine
go.drugbank.com/drugs/DB09226InvestigationalAs of May 2015, it is in phase III clinical trials for schizophrenia. … Brilaroxazine (RP5063) is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of schizophrenia and schizoaffective disorder.
1alpha,24S-Dihydroxyvitamin D2
go.drugbank.com/drugs/DB06117ExperimentalIt is developed for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease (CKD). Studies have shown LR-103 has the same potency as calcitriol, but much lower toxicity. … LR-103 is a naturally occurring D-hormone that is produced by the kidneys from vitamin D. LR-103 is one of the D-hormones produced from Hectorol.
Chlorophyll B
go.drugbank.com/drugs/DB04506ExperimentalIt is a component of both intra- and extracellular fluids and is excreted in the urine and feces. … Its salts are essential in nutrition, being required for the activity of many enzymes, especially those concerned with oxidative phosphorylation.
Categories: Heterocyclic Compounds with 4 or More Rings